{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:28Z","timestamp":1790409268696,"version":"4.1.0"},"reference-count":67,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>In the Phase 3 DREAMM\u20107 study of patients with relapsed\/refractory multiple myeloma (RRMM) who received \u2265\u20091 prior therapy, belantamab mafodotin plus bortezomib and dexamethasone (BVd) demonstrated a progression\u2010free survival (PFS) benefit versus daratumumab plus bortezomib and dexamethasone (DVd). This study aimed to indirectly compare the efficacy of BVd against alternative regimens in this patient population. A systematic literature review (SLR; December 2021\u2013February 4, 2024) was performed to identify relevant efficacy data. Studies were selected based on the Population\u2010Intervention\u2010Comparators\u2010Outcomes\u2010Study design framework criteria and independently reviewed for inclusion in the network meta\u2010analysis (NMA) if they had a connection to DREAMM\u20107 (approved in the US or EU, or likely to be a future DREAMM\u20107 comparator). Each trial had a common comparator arm, allowing for a connected network between the trials and linkage by shared treatments. The primary analysis was PFS in the intent\u2010to\u2010treat population from each study, and secondary analyses examined other endpoints. All endpoints were also evaluated in subgroups by lenalidomide\u2010exposure, \u2010refractoriness, and other patient characteristics. The SLR identified 12 comparator studies comprising 12 comparator regimens (each contained a proteasome inhibitor [bortezomib or carfilzomib] plus dexamethasone), all of which were included in the NMA with the DREAMM\u20107 study. BVd improved PFS versus all comparators, including daratumumab plus carfilzomib and dexamethasone, isatuximab plus carfilzomib and dexamethasone, and DVd. Overall survival was also improved by belantamab mafodotin plus bortezomib and dexamethasone over the other regimens. This study provides compelling evidence for belantamab mafodotin, plus bortezomib and dexamethasone, in early lines of treatment for RRMM.<\/jats:p>","DOI":"10.1002\/ajh.27661","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T19:35:38Z","timestamp":1743276938000},"page":"998-1009","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta\u2010Analysis"],"prefix":"10.1002","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"first","affiliation":[{"name":"Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Nooka","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodr\u00edguez\u2010Otero","sequence":"additional","affiliation":[{"name":"Cancer Center Clinica Universidad de Navarra  Pamplona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0569","authenticated-orcid":false,"given":"Fredrik","family":"Schjesvold","sequence":"additional","affiliation":[{"name":"Oslo Myeloma Center, Department of Hematology Oslo University Hospital  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-807X","authenticated-orcid":false,"given":"Eirini","family":"Katodritou","sequence":"additional","affiliation":[{"name":"Theagenio Cancer Hospital  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Combe","sequence":"additional","affiliation":[{"name":"FIECON  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Scott","sequence":"additional","affiliation":[{"name":"FIECON  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Cooper","sequence":"additional","affiliation":[{"name":"FIECON  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indeg","family":"Sly","sequence":"additional","affiliation":[{"name":"FIECON  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Ballew","sequence":"additional","affiliation":[{"name":"GSK  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Bitetti","sequence":"additional","affiliation":[{"name":"GSK  Zug Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Boytsov","sequence":"additional","affiliation":[{"name":"GSK  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Purser","sequence":"additional","affiliation":[{"name":"GSK  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"McNamara","sequence":"additional","affiliation":[{"name":"GSK, Stevenage  Hertfordshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34134"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0035"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0196-6"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34987"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(23)00243\u20100"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-6711"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00757-8"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02264-X"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19627"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00466-6"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010155"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/emermed-2020-209567"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_11_22_1","unstructured":"S.Dias N.Welton A.Sutton andA.Ades \u201cNICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta\u2010Analysis of Randomised Controlled Trials \u201d(2011) https:\/\/www.sheffield.ac.uk\/nice\u2010dsu\/tsds\/full\u2010list."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.10.007"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.04.012"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.623"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02734"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3065-z"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(14)70440\u20101"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(16)30147\u20108"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694604"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(15)00464\u20107"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.04.018"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.03.256"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010026"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(21)00579\u20109"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30354-1"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010023\u201000797\u20108"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282490"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137574"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01611-7"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102019\u2010123527"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8024"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.186"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00592-4"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194118"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26261"},{"key":"e_1_2_11_51_1","unstructured":"US Food and Drug Administration \u201cFDA Approves Carfilzomib and Daratumumab With Dexamethasone for Multiple Myeloma \u201d(2020) https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010carfilzomib\u2010and\u2010daratumumab\u2010dexamethasone\u2010multiple\u2010myeloma."},{"key":"e_1_2_11_52_1","unstructured":"U.S. Food and Drug Administration \u201cFDA Approves Isatuximab\u2010Irfc for Multiple Myeloma \u201d(2021) https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010isatuximab\u2010irfc\u2010multiple\u2010myeloma."},{"key":"e_1_2_11_53_1","unstructured":"U.S. Food and Drug Administration \u201cREVLIMID (lenalidomide) Highlights of the Prescribing Information \u201d (2017) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021880s049lbl.pdf."},{"key":"e_1_2_11_54_1","unstructured":"European Medicines Agency \u201cRevlimid Summary of Product Characteristics \u201dhttps:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/revlimid\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00217-X"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177546"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.163"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01296-2"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00750-2"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0592"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2023.100433"},{"key":"e_1_2_11_66_1","doi-asserted-by":"crossref","unstructured":"V.Hungria P.Robak M.Hus et\u00a0al. \u201cPatient\u2010Reported Outcomes (PROs) from the DREAMM\u20107 Randomized Phase 3 Study Comparing Belantamab Mafodotin Bortezomib and Dexamethasone (BVd) vs Daratumumab Bortezomib and Dexamethasone (DVd) in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM) \u201dPaper Presented at: ASCO2024.","DOI":"10.1016\/S2152-2650(24)00986-8"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.10.018"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2024.111537"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.27661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T09:49:05Z","timestamp":1754905745000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.27661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/ajh.27661"],"URL":"https:\/\/doi.org\/10.1002\/ajh.27661","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"2025-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}